- Home
- Publications
- Publication Search
- Publication Details
Title
Tim-3 expression and its role in hepatocellular carcinoma
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 11, Issue 1, Pages -
Publisher
Springer Nature America, Inc
Online
2018-10-11
DOI
10.1186/s13045-018-0667-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma
- (2018) Furong Liu et al. BULLETIN DU CANCER
- Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma
- (2018) Valerie Chew et al. GUT
- Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
- (2018) Shetal A. Patel et al. IMMUNITY
- Next generation of immune checkpoint therapy in cancer: new developments and challenges
- (2018) Julian A. Marin-Acevedo et al. Journal of Hematology & Oncology
- Genetic and phenotypic difference in CD8+T cell exhaustion between chronic hepatitis B infection and hepatocellular carcinoma
- (2018) Xiaochen Wang et al. JOURNAL OF MEDICAL GENETICS
- Hepatocellular carcinoma
- (2018) Alejandro Forner et al. LANCET
- The immunology of hepatocellular carcinoma
- (2018) Marc Ringelhan et al. NATURE IMMUNOLOGY
- Understanding the tumor immune microenvironment (TIME) for effective therapy
- (2018) Mikhail Binnewies et al. NATURE MEDICINE
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-κB/IL-6/STAT3 axis
- (2018) Hualin Zhang et al. ONCOGENE
- CAR T cell immunotherapy for human cancer
- (2018) Carl H. June et al. SCIENCE
- 14-3-3ζ delivered by hepatocellular carcinoma-derived exosomes impaired anti-tumor function of tumor-infiltrating T lymphocytes
- (2018) Xiaochen Wang et al. Cell Death & Disease
- Long non-coding RNA Lnc-Tim3 exacerbates CD8 T cell exhaustion via binding to Tim-3 and inducing nuclear translocation of Bat3 in HCC
- (2018) Jie Ji et al. Cell Death & Disease
- OX40 expression in hepatocellular carcinoma is associated with a distinct immune microenvironment, specific mutation signature, and poor prognosis
- (2018) Kunlin Xie et al. OncoImmunology
- Highly elevated soluble Tim-3 levels correlate with increased hepatocellular carcinoma risk and poor survival of hepatocellular carcinoma patients in chronic hepatitis B virus infection
- (2018) Fang Li et al. Cancer Management and Research
- Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas
- (2017) Guoying Zhou et al. GASTROENTEROLOGY
- Tim-3 and its role in regulating anti-tumor immunity
- (2017) Madhumita Das et al. IMMUNOLOGICAL REVIEWS
- Co-expression of TIM-3 and CEACAM1 promotes T cell exhaustion in colorectal cancer patients
- (2017) Yang Zhang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Clinical trials of CAR-T cells in China
- (2017) Bingshan Liu et al. Journal of Hematology & Oncology
- Chimeric antigen receptor T cells: a novel therapy for solid tumors
- (2017) Shengnan Yu et al. Journal of Hematology & Oncology
- Global trends and predictions in hepatocellular carcinoma mortality
- (2017) Paola Bertuccio et al. JOURNAL OF HEPATOLOGY
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- A TIM-3 Oligonucleotide Aptamer Enhances T Cell Functions and Potentiates Tumor Immunity in Mice
- (2017) Tal Gefen et al. MOLECULAR THERAPY
- Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update
- (2017) Masatoshi Kudo ONCOLOGY
- Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses
- (2017) Valerie Chew et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
- (2017) Levi J. Rupp et al. Scientific Reports
- PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR
- (2016) Elise A. Chong et al. BLOOD
- Dual Role of the Adaptive Immune System in Liver Injury and Hepatocellular Carcinoma Development
- (2016) Jessica Endig et al. CANCER CELL
- Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
- (2016) Jennifer E. Kim et al. CLINICAL CANCER RESEARCH
- T cell inflammation profile after surgical resection may predict tumor recurrence in HBV-related hepatocellular carcinoma
- (2016) Bin Song et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
- (2016) Leonid Cherkassky et al. JOURNAL OF CLINICAL INVESTIGATION
- Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma
- (2016) Zhu Li et al. MEDICINE
- NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis
- (2016) Chi Ma et al. NATURE
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model
- (2016) Eloah Rabello Suarez et al. Oncotarget
- Immunoglobulin Transporting Receptors Are Potential Targets for the Immunity Enhancement and Generation of Mammary Gland Bioreactor
- (2016) Xuemei Jiang et al. Frontiers in Immunology
- Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma
- (2016) Elly Marcq et al. OncoImmunology
- Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer
- (2016) Gulidanna Shayan et al. OncoImmunology
- Tumor-infiltrating Tim-3+ T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk
- (2016) Jing Li et al. OncoImmunology
- CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer
- (2016) Shu Su et al. OncoImmunology
- Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages
- (2015) Wenjiang Yan et al. GUT
- Decreased Tim-3 expression is associated with functional abnormalities of monocytes in decompensated cirrhosis without overt bacterial infection
- (2015) Yu Shi et al. JOURNAL OF HEPATOLOGY
- Regulation of HBV-specific CD8+ T cell-mediated inflammation is diversified in different clinical presentations of HBV infection
- (2015) Colin M. Dinney et al. JOURNAL OF MICROBIOLOGY
- T-cell immunoglobulin mucin-3 expression in bladder urothelial carcinoma: Clinicopathologic correlations and association with survival
- (2015) Meng Yang et al. JOURNAL OF SURGICAL ONCOLOGY
- Identification of TIM3 2’-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy
- (2015) Sandra Hervas-Stubbs et al. Oncotarget
- Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer
- (2015) Chiao-Wen Kang et al. Scientific Reports
- The Coordinated Actions of TIM-3 on Cancer and Myeloid Cells in the Regulation of Tumorigenicity and Clinical Prognosis in Clear Cell Renal Cell Carcinomas
- (2015) Y. Komohara et al. Cancer Immunology Research
- TGF-β upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin’s lymphoma
- (2014) Z-Z Yang et al. LEUKEMIA
- CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
- (2014) Yu-Hwa Huang et al. NATURE
- Association of T-Cell Immunoglobulin and Mucin Domain-Containing Molecule 3 (Tim-3) Polymorphisms with Susceptibility and Disease Progression of HBV Infection
- (2014) Jingyu Liao et al. PLoS One
- RepSox Slows Decay of CD34+Acute Myeloid Leukemia Cells and Decreases T Cell Immunoglobulin Mucin-3 Expression
- (2014) Audrey N. Jajosky et al. Stem Cells Translational Medicine
- Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
- (2013) L. B. John et al. CLINICAL CANCER RESEARCH
- αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma
- (2013) Xiao-Yong Huang et al. HEPATOLOGY
- Liver-primed CD8+T cells suppress antiviral adaptive immunity through galectin-9-independent T-Cell immunoglobulin and mucin 3 engagement of high-mobility group box 1 in mice
- (2013) Joseph S. Dolina et al. HEPATOLOGY
- Genetic variations of PD1 and TIM3 are differentially and interactively associated with the development of cirrhosis and HCC in patients with chronic HBV infection
- (2013) Zhu Li et al. INFECTION GENETICS AND EVOLUTION
- Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer
- (2013) Zhiqiang Guo et al. Journal of Translational Medicine
- Tim-3 Expression in Cervical Cancer Promotes Tumor Metastasis
- (2013) Yang Cao et al. PLoS One
- Tim-3 Expression Defines Regulatory T Cells in Human Tumors
- (2013) Jing Yan et al. PLoS One
- Cancer Immunotherapy
- (2013) J. Couzin-Frankel SCIENCE
- TIM-3 expression in human osteosarcoma: Correlation with the expression of epithelial-mesenchymal transition-specific biomarkers
- (2013) YONGJUN SHANG et al. Oncology Letters
- Galectin-9 and IL-21 Mediate Cross-regulation between Th17 and Treg Cells during Acute Hepatitis C
- (2013) Hassen Kared et al. PLoS Pathogens
- Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
- (2013) Liza B John et al. OncoImmunology
- TIM3+FOXP3+regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer
- (2013) Kaori Sakuishi et al. OncoImmunology
- Ectopic Expression of TIM-3 in Lung Cancers
- (2012) Xuewei Zhuang et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9
- (2012) M. K. Gleason et al. BLOOD
- Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors
- (2012) Hyo Jin Park et al. CELLULAR IMMUNOLOGY
- Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer
- (2012) Alexander Pedroza-Gonzalez et al. HEPATOLOGY
- Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma
- (2012) Hang Li et al. HEPATOLOGY
- Antigen-Independent Induction of Tim-3 Expression on Human T Cells by the Common -Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Is Associated with Proliferation and Is Dependent on the Phosphoinositide 3-Kinase Pathway
- (2012) S. Mujib et al. JOURNAL OF IMMUNOLOGY
- Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
- (2012) Shigeki Chiba et al. NATURE IMMUNOLOGY
- TIM3 gene polymorphisms in patients with chronic hepatitis B virus infection: impact on disease susceptibility and hepatocellular carcinoma traits
- (2012) Z. Li et al. TISSUE ANTIGENS
- The Inflammatory Microenvironment in Hepatocellular Carcinoma: A Pivotal Role for Tumor-Associated Macrophages
- (2012) Daria Capece et al. Biomed Research International
- Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia
- (2011) Q. Zhou et al. BLOOD
- Anti-TIM3 Antibody Promotes T Cell IFN- -Mediated Antitumor Immunity and Suppresses Established Tumors
- (2011) S. F. Ngiow et al. CANCER RESEARCH
- T-cell immunoglobulin and mucin domain 3 genetic polymorphisms are associated with rheumatoid arthritis independent of a shared epitope status
- (2011) Yeong Wook Song et al. HUMAN IMMUNOLOGY
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B
- (2010) Ying Ju et al. JOURNAL OF HEPATOLOGY
- Tim-3/Galectin-9 Pathway: Regulation of Th1 Immunity through Promotion of CD11b+Ly-6G+ Myeloid Cells
- (2010) V. Dardalhon et al. JOURNAL OF IMMUNOLOGY
- T Cell/Transmembrane, Ig, and Mucin-3 Allelic Variants Differentially Recognize Phosphatidylserine and Mediate Phagocytosis of Apoptotic Cells
- (2010) Rosemarie H. DeKruyff et al. JOURNAL OF IMMUNOLOGY
- Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation
- (2009) M. Nakayama et al. BLOOD
- A Small-Molecule Inhibitor of Tgf-β Signaling Replaces Sox2 in Reprogramming by Inducing Nanog
- (2009) Justin K. Ichida et al. Cell Stem Cell
- Multiple roles for CD4+T cells in anti-tumor immune responses
- (2008) Richard Kennedy et al. IMMUNOLOGICAL REVIEWS
- TIM-3 polymorphisms in type 1 diabetes families
- (2008) Patrick Brück et al. JOURNAL OF HUMAN GENETICS
- The tumor microenvironment and its role in promoting tumor growth
- (2008) T L Whiteside ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More